ChemoCentryx Inc. (NASDAQ:CCXI) dropped 20.2% during mid-day trading on Monday . The stock traded as low as $4.16 and last traded at $4.22, with a volume of 1,021,500 shares trading hands. The stock had previously closed at $5.29.

CCXI has been the subject of several research analyst reports. JPMorgan Chase & Co. reiterated a “buy” rating and set a $11.00 target price on shares of ChemoCentryx in a research report on Tuesday, August 9th. Cowen and Company reiterated a “hold” rating on shares of ChemoCentryx in a research report on Thursday, May 19th. Finally, Zacks Investment Research lowered shares of ChemoCentryx from a “buy” rating to a “hold” rating in a research report on Monday, May 16th.

The company has a 50-day moving average of $4.61 and a 200-day moving average of $3.89. The firm’s market cap is $201.56 million.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.